Miniatures Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase 1 Production
暂无分享,去创建一个
R. Kiessling | J. Hansson | G. Masucci | I. Poschke | Y. Mao | G. Gentilcore | M. Nyström | Coaña Pico de Yago | Yago Pico deCoa | YumengMao | Maria Nystr
[1] R. Kiessling,et al. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients , 2012, Oncoimmunology.
[2] J. Wolchok,et al. Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials , 2012 .
[3] R. Kiessling,et al. On the armament and appearances of human myeloid-derived suppressor cells. , 2012, Clinical immunology.
[4] Chris Fellner. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. , 2012, P & T : a peer-reviewed journal for formulary management.
[5] Daohai Yu,et al. Biomarkers on melanoma patient T Cells associated with ipilimumab treatment , 2012, Journal of Translational Medicine.
[6] C. Drake,et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.
[7] S. Chasalow,et al. Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.
[8] L. Walker,et al. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses , 2011, Nature Reviews Immunology.
[9] A. Lefvert,et al. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation , 2011, BMC Immunology.
[10] J. Wolchok,et al. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. , 2010, Seminars in oncology.
[11] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[12] M. Manns,et al. CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice , 2010, The Journal of Immunology.
[13] M. Atkins,et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.
[14] Yuan Zhang,et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells , 2009, Cancer Immunology, Immunotherapy.
[15] B. Kavanagh,et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. , 2008, Blood.
[16] Paolo Serafini,et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.
[17] L. Polito,et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. , 2003, Blood.
[18] G. Freeman,et al. Expression and Regulation of the PD‐L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells , 2002, Microcirculation.
[19] A. Sharpe,et al. CTLA‐4 regulates cell cycle progression during a primary immune response , 2002, European journal of immunology.
[20] A. Ramsay,et al. IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE). , 2002, Scandinavian journal of immunology.
[21] D. Xu,et al. Expression of CTLA‐4 by Human Monocytes , 2002, Scandinavian journal of immunology.
[22] 岩井 佳子. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation , 2002 .
[23] G. Doria,et al. Inhibition of IgG1 and IgE Production by Stimulation of the B Cell CTLA-4 Receptor1 , 2000, The Journal of Immunology.
[24] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.